COVID-19 - Revision history

Ostermayer at 18:15, 16 January 2026

2026-01-16T18:15:25Z

← Older revision		Revision as of 18:15, 16 January 2026
Line 1:		Line 1:
	{{~~Adult top}} [[~~COVID-19 (peds)]]. For pregnant patients see [[COVID-19 in pregnancy]].''		{{AdultPage\|COVID-19 (peds)}}. For pregnant patients see [[COVID-19 in pregnancy]].''
	==Background==		==Background==
	*Caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)		*Caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Rossdonaldson1: /* References */

2024-02-07T18:30:42Z

References

← Older revision		Revision as of 18:30, 7 February 2024
Line 293:		Line 293:

	[[Category:ID]]		[[Category:ID]]
	~~[[Category:COVID-19]]~~

Rossdonaldson1: /* Medical Management by Patient Category */

2022-01-18T20:58:20Z

Medical Management by Patient Category

← Older revision		Revision as of 20:58, 18 January 2022
Line 196:		Line 196:
	**Consider [[COVID-19:_Medication_therapy#Anticoagulation\|anticoagulation]]		**Consider [[COVID-19:_Medication_therapy#Anticoagulation\|anticoagulation]]

	===~~Medical Management~~ by Patient Category===		===Medications by Patient Category===
	[[File:Outpatient Fig 1.png\|thumb\|NIH consensus guidelines for COVID treatment.<ref>https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/clinical-management-summary/</ref>]]		[[File:Outpatient Fig 1.png\|thumb\|NIH consensus guidelines for COVID treatment.<ref>https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/clinical-management-summary/</ref>]]
	[[File:Inpatient Fig 2.png\|thumb\|NIH consensus guidelines for COVID treatment.<ref>https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/clinical-management-summary/</ref>]]		[[File:Inpatient Fig 2.png\|thumb\|NIH consensus guidelines for COVID treatment.<ref>https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/clinical-management-summary/</ref>]]

	====Outpatients Not Requiring Admission<ref>https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/clinical-management-summary/</ref>====		====Outpatients Not Requiring Admission<ref>https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/clinical-management-summary/</ref>====
	*Isolation precautions
	*High risk patients (one of the following, if available):		*High risk patients (one of the following, if available):
	**Ritonavir-boosted nirmatrelvir ([[Paxlovid]])		**Ritonavir-boosted nirmatrelvir ([[Paxlovid]])
Line 210:		Line 209:

	====Outpatients Requiring Home Oxygen (New or Increased)<ref>https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/clinical-management-summary/</ref>====		====Outpatients Requiring Home Oxygen (New or Increased)<ref>https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/clinical-management-summary/</ref>====
	*Isolation precautions
	*[[Dexamethasone]] 6mg PO daily x the duration of supplemental oxygen (not to exceed 10 days)		*[[Dexamethasone]] 6mg PO daily x the duration of supplemental oxygen (not to exceed 10 days)
	*Consider [[Remdesivir]]		*Consider [[Remdesivir]]

Rossdonaldson1: /* Management */

2022-01-18T20:57:32Z

Management

@@ Line 170: / Line 170: @@
 {{COVID PPE summary table}}
-===Management by Patient Category===
+===General Supportive Care===
 [[File:Outpatient Fig 1.png|thumb|NIH consensus guidelines for COVID treatment.<ref>https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/clinical-management-summary/</ref>]]
 [[File:Inpatient Fig 2.png|thumb|NIH consensus guidelines for COVID treatment.<ref>https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/clinical-management-summary/</ref>]]
@@ Line 197: / Line 223: @@
 *If requiring High-Flow or NIV, add [[baricitinib]] or IV [[tocilizumab]]
 **If not available, IV [[sarilumab]] can be used
 ==[[Respiratory failure]]==

Rossdonaldson1: /* Harbor */

2022-01-18T20:46:54Z

Harbor

@@ Line 222: / Line 222: @@
 *Vascular
 **Consider [[COVID-19:_Medication_therapy#Anticoagulation|anticoagulation]]
 ==[[Respiratory failure]]==

Rossdonaldson1: /* Harbor */

2022-01-18T20:45:31Z

Harbor

← Older revision		Revision as of 20:45, 18 January 2022
Line 238:		Line 238:
	***Neurodevelopmental disorders		***Neurodevelopmental disorders
	***A medical-related technological dependence (ex., tracheostomy)		***A medical-related technological dependence (ex., tracheostomy)

	*Tocilizumab: IL-6 antagonist
	**Trials show that may improved survival and other clinical outcomes in patients in admitted severe disease

	*Casirivimab+imdevimab ('''REGEN-COV''' from company Regeneron) for high risk patients being discharged with COVID:		*Casirivimab+imdevimab ('''REGEN-COV''' from company Regeneron) for high risk patients being discharged with COVID:

Rossdonaldson1: /* Harbor */

2022-01-18T20:43:27Z

Harbor

← Older revision		Revision as of 20:43, 18 January 2022
Line 238:		Line 238:
	***Neurodevelopmental disorders		***Neurodevelopmental disorders
	***A medical-related technological dependence (ex., tracheostomy)		***A medical-related technological dependence (ex., tracheostomy)

	*'''Sotrovimab''' newer, very limited supply
	** Seems to be effective against omicron
	** 500 mg IV over 30 min, observe for 1 hour after

	*Tocilizumab: IL-6 antagonist		*Tocilizumab: IL-6 antagonist

Rossdonaldson1: /* Harbor */

2022-01-18T20:27:39Z

Harbor

← Older revision		Revision as of 20:27, 18 January 2022
Line 224:		Line 224:

	====Harbor====		====Harbor====
	* '''Molnupiravir''' (Merck)
	** Ages 18 and older only, mild to moderate disease only
	** Within 5 days of symptom onset
	** 800 mg q12hr x 5d
	** Phase 3 trial showed 30% reduction in risk of hospitalization or death
	** Avoid in pregnant or young patients given concern for mutagenicity

	'''Monoclonal antibodies'''		'''Monoclonal antibodies'''
	*High risk patients within 10d of symptom onset, age 12 yo and above		*High risk patients within 10d of symptom onset, age 12 yo and above

Rossdonaldson1: /* Harbor */

2022-01-18T20:19:23Z

Harbor

@@ Line 224: / Line 224: @@
 ====Harbor====
 * '''Molnupiravir''' (Merck)
 ** Ages 18 and older only, mild to moderate disease only

Rossdonaldson1: /* Harbor */

2022-01-18T20:16:09Z

Harbor

← Older revision		Revision as of 20:16, 18 January 2022
Line 224:		Line 224:

	====Harbor====		====Harbor====
	*Remdesivir for patients who require hospitalization with supplemental oxygen, excludes mechanical ventilation, BiPAP.
	**200 mg IV on Day 1, then 100 mg once daily on Days 2 and 3 w/in 7d of symptom onset

	~~'''Oral antiviral agents'''~~
	*Given limited supply, prioritize:
	**Treatment of COVID-19 in unvaccinated or incompletely vaccinated individuals with clinical risk factors for severe illness and immune compromised vaccinated individuals > vaccinated with risk factors
	**[https://lacounty.sharepoint.com/sites/dhs-orchid/ORCHID%20Training/Forms/AllItems.aspx?csf=1&e=mRmvCz&cid=466f7f14%2Dcbfc%2D404d%2D8d4a%2D49e70af92fdc&FolderCTID=0x01200018D0144890F41D489A369B333E884F98&id=%2Fsites%2Fdhs%2Dorchid%2FORCHID%20Training%2FORCHID%20Course%20Materials%2FORCHID%20%20Job%20Aids%2FMolnupiravir%20and%20Nirmatrelvir%20Prescribing%20Job%20Aid%2Epdf&parent=%2Fsites%2Fdhs%2Dorchid%2FORCHID%20Training%2FORCHID%20Course%20Materials%2FORCHID%20%20Job%20Aids&CT=1641978455645&OR=OWA-NT&CID=c179fe0d-9183-7623-af59-f7f1482fa328 ORCHID job aid on e-prescribing COVID oral therapies]

	*Nirmatrelvir tablets and ritonavir tablets ('''Paxlovid''' from Pfizer)		*Nirmatrelvir tablets and ritonavir tablets ('''Paxlovid''' from Pfizer)
	**treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms) that are high risk		**treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms) that are high risk